SUBLOCADE
AssetAlso called Buprenorphine, Brixadi, Bupeaze, Buplast
Provides extended-release buprenorphine by subcutaneous injection.
- Stage
- Approved
- Modality
- Not known
- Target
- OPRM1
- 14
- Indications
- 259
- Trials
- 1
- Developer
Approved by the FDA on Nov 30, 2017 (NDA209819). FDA
Indications
14Opioid use disorder
Approved, indivior.com
Moderate to Severe Opioid Use Disorder
Approved, FDA
Opioid-related disorders
Phase 3, Completed, NCT02357901, clinicaltrials.gov, Nov 12, 2026
11 more
In the full profile
- Target and mechanism3
- Owner and partners1
- Trials259
- Evidence for its targets3
- Competitors12
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.